Brave Fight Against Cancer & Tumors

We are a bio-startup that aims to solve unmet medical needs for refractory tumors and rare diseases

Vision・Technology

Members

NOBUTOSHI ESAKI Ph.D.
CEO, Co-Founder

Born in 1990 in Okawa, Fukuoka, Japan. Complete Ph.D. course in Nagoya University Graduate School of Medicine in 2020. Research and develop “stromal targeting therapy for tumor”, and created and analyzed a prototype, which led to the founding of BFACT Co., Ltd.. Motto is “Anymore, we have to do something about unmet medical needs”. Pastime: Watching basketball and mixed martial arts (and sometimes listening to classical music).

ATSUSHI ENOMOTO M.D, Ph.D.
Co-Founder

Professor, Department of Tumor Pathology, Nagoya University School of Medicine. Has been engaged in basic research on transporters and intracellular scaffold proteins. Currently, Has been working on mesenchymal stem cells (MSCs) and cancer-associated fibroblast cells (CAFs).

News

Sep. 2024, Grant from the Japan Agency for Medical Research and Development was adopted https://www.amed.go.jp/koubo/11/01/1101C_00088.html
Feb. 2024, ESAKI CEO presented our research at the 7th Annual Meeting of Japanese Association of Sarcoma Treatment and Research https://jstar2024.org/

Dec. 2023, ESAKI CEO presented our research at the 2nd Annual Meeting of the Antibody Society of Japan https://antibodysociety.jp/wp-content/uploads/2023/10/%E7%AC%AC%EF%BC%92%E5%9B%9E-%E6%97%A5%E6%9C%AC%E6%8A%97%E4%BD%93%E5%AD%A6%E4%BC%9A%E5%AD%A6%E8%A1%93%E5%A4%A7%E4%BC%9A-%E5%8F%A3%E9%A0%AD%E7%99%BA%E8%A1%A8%E3%83%97%E3%83%AD%E3%82%B0%E3%83%A9%E3%83%A020231026.pdf

Sep. 2023, Grant from The Small and Medium Enterprise Agency was adopted https://www.chusho.meti.go.jp/keiei/sapoin/2023/230622saitaku01.pdf?0904

May. 2023, Third-party allotment of approximately 100M jpy as pre-series A round https://bfact.jp/wp-content/uploads/2023/09/e8b387e98791e8aabfe98194-e383aae383aae383bce382b9-e88bb1e8aa9ee78988.pdf

Apr. 2023, Research grant (research fostering type) from the Tokai Foundation for Industrial Technology Promotion was adopted https://www.tft.or.jp/第35回（令和４年度募集）研究助成-採択者

Feb. 2023, ESAKI CEO received the award at the 6th Annual Meeting of Japanese Association of Sarcoma Treatment and Research https://jstar2023.org/index.html

Oct. 2022, Our founder, Professor Atsushi Enomoto of Nagoya University, has been selected for the “Innovative Research Project for Practical Application of Cancer Therapy” (3-1) by the Japan Agency for Medical Research and Development (AMED) https://www.amed.go.jp/koubo/15/01/1501C_00058.html

May. 2022, New Aichi Creative R&D Grant (Trial Type) was adopted https://www.pref.aichi.jp/uploaded/attachment/420367.pdf

Apr. 2022, ESAKI CEO spoke on the radio program StartupN https://startup-n.com/guest/archives/5816

Apr. 2022, Nikkan Kogyo Shimbun published an article about BFACT https://newswitch.jp/p/31536

Jan. 2022, ESAKI CEO spoke at Kyoto University Innovation Capital Co., Ltd.’s event. https://www.kyoto-u.ac.jp/ja/event/2021-12-23 https://www.kyoto-u.ac.jp/ja/event/2021-12-23

Nov. 2021, We received an award at the “GLOW Pitch” presentation event hosted by Nagoya city https://nagoya-innovation.jp/news/2021/11/glow_pitch-.html

June. 2021, signed a license agreement with Tokai National Higher Education and Research System and Sowakai Shigei Medical Research Institute.

May. 2021, started a joint research project with the Tokai National Higher Education and Research System

Dec. 2020, Third-party allotment of approximately 10M jpy to ANRI Inc. (Headquarters: Shibuya-ku, Tokyo) as seed round

Nov. 2020, BFACT Co., Ltd. was founded

Contact

Headquarters: STATION Ai, 1-2-32, Tsurumai, Showa-ku, Nagoya, Aichi, Japan.
Post code: 466-0064

e-mail: info@bfact.co.jp